Free Trial

Cabaletta Bio (NASDAQ:CABA) Upgraded to Sell at Wall Street Zen

Cabaletta Bio logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Cabaletta Bio from “strong sell” to “sell.” Despite the downgrade, analysts’ consensus rating is “Moderate Buy,” with an average price target of $15.60.
  • Cabaletta Bio shares opened at $1.30, near the stock’s 52-week low of $1.18; its 50-day and 200-day moving averages were $2.12 and $2.82, respectively.
  • The company reported a quarterly loss of $0.28 per share, beating the consensus estimate of a $0.32 loss. Analysts expect a loss of $1.34 per share for the current year.
  • MarketBeat previews top five stocks to own in December.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) was upgraded by analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a report issued on Saturday, Wall Street Zen reports.

CABA has been the subject of a number of other reports. Wells Fargo & Company cut their price objective on Cabaletta Bio from $4.00 to $3.00 and set an "equal weight" rating for the company in a research report on Friday, August 14th. William Blair upgraded Cabaletta Bio to a "strong-buy" rating in a research report on Wednesday, September 23rd. HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Cabaletta Bio in a research note on Tuesday, September 1st. TD Cowen raised shares of Cabaletta Bio to a "strong-buy" rating in a report on Monday, August 24th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Cabaletta Bio in a research report on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $15.60.

Get Our Latest Report on CABA

Cabaletta Bio Stock Up 1.6%

Shares of Cabaletta Bio stock opened at $1.30 on Friday. The stock's fifty day moving average is $2.12 and its two-hundred day moving average is $2.82. The company has a market capitalization of $220.40 million, a PE ratio of -0.92 and a beta of 3.56. Cabaletta Bio has a 52 week low of $1.18 and a 52 week high of $4.23.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, research analysts anticipate that Cabaletta Bio will post -1.34 earnings per share for the current year.

Hedge Funds Weigh In On Cabaletta Bio

Several hedge funds and other institutional investors have recently made changes to their positions in CABA. Legal & General Group Plc purchased a new stake in shares of Cabaletta Bio in the second quarter valued at approximately $34,000. HighTower Advisors LLC acquired a new position in shares of Cabaletta Bio during the 2nd quarter worth approximately $34,000. Kestra Advisory Services LLC purchased a new stake in shares of Cabaletta Bio in the first quarter valued at $32,000. SummitTX Capital L.P. acquired a new stake in Cabaletta Bio during the first quarter worth approximately $34,000. Finally, StoneX Group Inc. acquired a new stake in shares of Cabaletta Bio during the third quarter worth $26,000.

About Cabaletta Bio

(Get Free Report)

Cabaletta Bio, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company's approach is designed to selectively eliminate disease-causing immune cells and potentially provide durable disease remission rather than relying on continuous immunosuppression.

Its lead investigational product, CABA-201, is an autologous, fully human CD19 chimeric antigen receptor T-cell therapy designed to target and eliminate CD19-positive B cells.

Read More

Analyst Recommendations for Cabaletta Bio (NASDAQ:CABA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cabaletta Bio Right Now?

Before you consider Cabaletta Bio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabaletta Bio wasn't on the list.

While Cabaletta Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines